Novo Nordisk Expected to Raise Full-Year Guidance on Strong Q3 Results
J.P. Morgan analysts anticipate Novo Nordisk will report strong third-quarter results and subsequently raise its full-year guidance. The bank forecasts adjusted sales of 76 billion Danish kroner, exceeding Bloomberg consensus by 4%. Injectable Wegovy sales are projected to reach 21.5 billion kroner, 9% above consensus.